AJANTPHARM2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member AJANTPHARM2019-10-012019-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2019-10-012019-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member AJANTPHARM2019-10-012019-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member AJANTPHARM2019-10-012019-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AJANTPHARM 2019-04-01 2020-03-31 2020-01-20 INR Crores Third quarter Single segment PHARMACEUTICAL 2019-10-01 2019-12-31 Unaudited Consolidated 6512100000.00 146400000.00 6658500000.00 1383400000.00 241500000.00 66000000.00 1203800000.00 15700000.00 236000000.00 1757700000.00 4904100000.00 1754400000.00 -3400000.00 1751000000.00 634400000.00 41100000.00 675500000.00 0.00 1075500000.00 0.00 0.00 0.00 0.00 1075500000.00 18300000.00 1093800000.00 1093800000.00 0.00 175400000.00 2 12.33 12.32 0.00 0.00 12.33 12.32 1. The above consolidated results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 5 February 2020. n2. Statutory Auditors have carried out Limited Review of the consolidated financial results for the quarter and nine month ended 31 December 2019. n3. The consolidated unaudited financial results of the Company, its wholly owned subsidiaries and step-down subsidiary (“the Group”) have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest. n4. During the quarter, Nil (nine month 7,500) equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by Rs.Nil Nine month Rs. 15,000) and securities premium account by Rs Nil (nine month Rs. 0.93 crores). n5. The Group operates exclusively in one reportable business segment i.e Pharmaceuticals. n6. The Group has adopted the modified retrospective approach as per Ind AS 116 - Leases to account for its leases, effective from reporting periods beginning 1 April 2019. This has resulted in recognising right of use assets of Rs. 34.97 crores and a corresponding lease liability of Rs. 39.02 crores by adjusting retained earnings by Rs. 2.65 crores (net of deferred tax of Rs. 1.40 crores) as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from rent to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. Due to this change, current quarter profit before tax is lower by Rs. Nil (nine month Rs. 0.17 crores). To this extent, performance for the current period ended 31 December 2019 is not comparable with previous period results. n7. Pursuant to a fire incident on 31 August 2019 at Guwahati plant, certain property, plant and equipment and inventory were damaged. The Company has lodged an initial estimate of loss with the insurance company and the survey is currently in process. The Company has recorded a loss of Rs. 23.27 crores towards impairment of part of property, plant and equipment and inventory arising from the incident. The Company has also recognised a minimum insurance claim receivable of Rs. 21.86 cr. in the current nine month, for which auditor has given modified opinion. However, Company is confident of receiving the said claim. The aforementioned loss and the income from insurance claim receivable has been presented under exceptional item in the financial result with a net impact of Rs. 1.41 cr. The Company is in process of determining its final claim and will make adjustments to the estimated loss when the assessment is completed. n8. Figures for the previous period's have been regrouped, wherever necessary, to correspond with the figures of the current period. n9. The Standalone Financial Results are available on the company's website www.ajantapharma.com. Single segment 2019-04-01 2019-12-31 Unaudited Consolidated 19059100000.00 355000000.00 19414100000.00 3868000000.00 824400000.00 88700000.00 3561100000.00 82900000.00 696800000.00 5397000000.00 14518900000.00 4895200000.00 -14100000.00 4881100000.00 1368200000.00 127500000.00 1495700000.00 0.00 3385400000.00 0.00 0.00 0.00 0.00 3385400000.00 6700000.00 3392100000.00 3392100000.00 0.00 175400000.00 2 38.80 38.79 0.00 0.00 38.80 38.79 Other Expenses 1757700000.00 Other Expenses 5397000000.00